NBZ Investment Advisors LLC Invests $90,000 in SPDR S&P Biotech ETF (NYSEARCA:XBI)

NBZ Investment Advisors LLC bought a new stake in shares of SPDR S&P Biotech ETF (NYSEARCA:XBIFree Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,000 shares of the exchange traded fund’s stock, valued at approximately $90,000.

Several other institutional investors also recently bought and sold shares of the company. Addison Advisors LLC raised its stake in SPDR S&P Biotech ETF by 27.4% in the 4th quarter. Addison Advisors LLC now owns 535 shares of the exchange traded fund’s stock worth $48,000 after acquiring an additional 115 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in SPDR S&P Biotech ETF by 0.6% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 23,873 shares of the exchange traded fund’s stock worth $2,373,000 after buying an additional 148 shares during the last quarter. Invst LLC lifted its stake in SPDR S&P Biotech ETF by 6.0% during the 3rd quarter. Invst LLC now owns 2,807 shares of the exchange traded fund’s stock valued at $277,000 after acquiring an additional 160 shares during the period. Beech Hill Advisors Inc. increased its stake in shares of SPDR S&P Biotech ETF by 2.5% in the fourth quarter. Beech Hill Advisors Inc. now owns 6,655 shares of the exchange traded fund’s stock worth $599,000 after acquiring an additional 162 shares during the period. Finally, Wealth Alliance raised its holdings in shares of SPDR S&P Biotech ETF by 4.4% during the fourth quarter. Wealth Alliance now owns 4,083 shares of the exchange traded fund’s stock worth $368,000 after purchasing an additional 173 shares during the last quarter.

SPDR S&P Biotech ETF Stock Performance

NYSEARCA XBI opened at $85.53 on Friday. The stock has a 50-day simple moving average of $89.48 and a two-hundred day simple moving average of $94.06. The firm has a market capitalization of $5.54 billion, a P/E ratio of 11.47 and a beta of 0.99. SPDR S&P Biotech ETF has a fifty-two week low of $81.14 and a fifty-two week high of $105.47.

SPDR S&P Biotech ETF Cuts Dividend

The firm also recently announced a dividend, which was paid on Wednesday, March 26th. Stockholders of record on Monday, March 24th were paid a dividend of $0.0053 per share. The ex-dividend date was Monday, March 24th.

About SPDR S&P Biotech ETF

(Free Report)

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Featured Stories

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBIFree Report).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.